Marker Therapeutics, Inc.
MRKRDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Low dose FRα vaccine | Phase 2 | Breast Cancer | - | - |
TPIV200 | Phase 2 | Ovarian Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Marker Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Marker Therapeutics, Inc.'s (MRKR) pipeline across Phase 2. Its lead program is Low dose FRα vaccine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Marker Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Marker Therapeutics, Inc. (MRKR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MRKR biotech catalysts?→
Add MRKR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Marker Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.